Sellas Life Sciences Group Inc

SLS is in a Stage 2 advancing phase with a corrective reset after a parabolic spike. The medium-term bias remains bullish, supported by rising moving averages and structural integrity, while the short-term pullback into the rising 9 EMA/21 EMA area offers a favorable entry with no exhaustion signals present.

• ↑78/80 deaths collected in REGAL Phase 3 trial, readout imminent.
• ↑$107.1M cash reserves support GPS development and strategic priorities.
• ↓24.5× price-to-book signals stretched valuation amid biotech volatility.